

REMARKS

Claims 1, 3, 5, 6, 8, 10, 12, 14, 16, 18, 21, 36, and 17 are pending in the application. Claims 1, 3, 5, 6, 8, 10, 12, 14, 16, 18, 21, 36, and 17 are allowed.

Supplemental Information Disclosure Statement

Applicants make available to the Patent and Trademark Office a Supplemental Information Disclosure Statement on form PTO/SB/08B and a copy of the art cited thereon. Applicants respectfully request that the Examiner consider carefully the complete text of the cited reference(s) in connection with the continued examination of the above-identified application in accord with 37 CFR §1.104(a).

It is respectfully requested that all cited reference(s) considered by the Examiner be listed in the "References Cited" portion of any patent issuing from the instant application (MPEP § 1302.12).

Conclusion

Applicants respectfully request continued examination under 37 C.F.R. § 1.114 of Claims 1, 3, 5, 6, 8, 10, 12, 14, 16, 18, 21, 36, and 17. The undersigned would welcome a telephone call from the Examiner to discuss any matters related to this case that the Examiner thinks are amenable to resolution by such discussion.

Respectfully submitted,

Date: May 5, 2004

Claude F. Purchase, Jr.

Claude F. Purchase, Jr.
Reg. No. 47,871
Pfizer Inc.
2800 Plymouth Road
Ann Arbor, MI 48105
Tel. (734) 622-1692
Fax (734) 622-1553